Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research

Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research

Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research

Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research

Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research

Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research

Multimodal prehabilitation in elective oncological colorectal surgery enhances preoperative physical fitness: a single center prospective real-world data analysis
CONCLUSION: Prehabilitation in elective oncological colorectal surgery is associated with enhanced preoperative physical fitness regardless of baseline performance. Improvements were relatively larger in less fit patients.PMID:38477370 | DOI:10.2340/1651-226X.2024.20287 (Source: Acta Oncologica)
Source: Acta Oncologica - March 13, 2024 Category: Cancer & Oncology Authors: David W G Ten Cate Charissa R Sabajo Charlotte J L Molenaar Loes Janssen Bart C Bongers Gerrit D Slooter Source Type: research

Multimodal prehabilitation in elective oncological colorectal surgery enhances preoperative physical fitness: a single center prospective real-world data analysis
CONCLUSION: Prehabilitation in elective oncological colorectal surgery is associated with enhanced preoperative physical fitness regardless of baseline performance. Improvements were relatively larger in less fit patients.PMID:38477370 | DOI:10.2340/1651-226X.2024.20287 (Source: Acta Oncologica)
Source: Acta Oncologica - March 13, 2024 Category: Cancer & Oncology Authors: David W G Ten Cate Charissa R Sabajo Charlotte J L Molenaar Loes Janssen Bart C Bongers Gerrit D Slooter Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature
Acta Oncol. 2024 Feb 29;63:1-2. doi: 10.2340/1651-226X.2024.40158.ABSTRACTCorrigendum for article: DOI: 10.1080/0284186X.2023.2281005.PMID:38421054 | DOI:10.2340/1651-226X.2024.40158 (Source: Acta Oncologica)
Source: Acta Oncologica - February 29, 2024 Category: Cancer & Oncology Authors: Mef Nilbert Jakob Eberhard Jenny Engdahl Severin Marcus Edelhamre Filip Torle Dejan Korkocic Fredrik J örgren Source Type: research